|1.||Charlton, Peter A: 2 articles (10/2005 - 12/2004)|
|2.||Mistry, Prakash: 2 articles (10/2005 - 10/2004)|
|3.||Scott, John A: 1 article (10/2005)|
|4.||Brown, Jeffrey L: 1 article (10/2005)|
|5.||Harris, Susan M: 1 article (10/2005)|
|6.||Knight, Louise A: 1 article (12/2004)|
|7.||Mercer, Stuart J: 1 article (12/2004)|
|8.||Cree, Ian A: 1 article (12/2004)|
|9.||Di Nicolantonio, Federica: 1 article (12/2004)|
|10.||Norris, David: 1 article (12/2004)|
10/29/2004 - "The new bisphenazine anticancer drug MLN944 is a novel cytotoxic agent with exceptional anti-tumor activity against a range of human and murine tumor models both in vitro and in vivo. "
01/01/2004 - "MLN944 (XR5944) is a novel bis-phenazine that has demonstrated exceptional efficacy against a number of murine and human tumor models. "
10/01/2005 - "XR5944 (MLN944) is a novel bis-phenazine currently in phase I clinical trials that has demonstrated potent cytotoxic activity against a variety of tumor models. "
12/01/2004 - "The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples."
01/01/2004 - "Finally, transcriptional profiling analysis of xenograft tumors treated with MLN944 revealed clusters of regulated genes distinct from those observed in irinotecan hydrochloride (CPT-11)-treated tumors. "
|2.||DNA (Deoxyribonucleic Acid)
|1.||Heterologous Transplantation (Xenotransplantation)